Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Tokyo
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Kyowa Hakko Kirin Co Ltd

+ Add to Watchlist

4151:JP

1,336.0 JPY 7.0 0.52%

As of 01:00:00 ET on 01/29/2015.

Snapshot for Kyowa Hakko Kirin Co Ltd (4151)

Open: 1,325.0 Day's Range: 1,315.0 - 1,347.0 Volume: 1,527,000
Previous Close: 1,343.0 52wk Range: 1,006.0 - 1,510.0 1-Yr Rtn: +24.33%

Stock Chart for 4151

No chart data available.
  • 4151:JP 1,337.0
  • 1D
  • 1M
  • 1Y
1,343.0
Interactive 4151 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 4151

Current P/E Ratio (ttm) 38.9164
Estimated P/E(12/2014) 43.1051
Relative P/E vs. TPX 2.4010
Earnings Per Share (JPY) (ttm) 34.3300
Est. EPS (JPY) (12/2014) 30.9940
Est. PEG Ratio -
Market Cap (M JPY) 770,182.03
Shares Outstanding (M) 576.48
30 Day Average Volume 1,744,800
Price/Book (mrq) 1.2271
Price/Sale (ttm) 2.2333
Dividend Indicated Gross Yield 1.87%
Cash Dividend (JPY) 12.5000
Dividend Ex-Date 12/26/2014
5 Year Dividend Growth 10.76%
Next Earnings Announcement 01/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 4151

  • Revenue
  • Net Income (M/JPY)
  • Profit Margin (%)

Company Profile & Key Executives for 4151

Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.

Nobuo HanaiPresidentHiroyuki KawaiExecutive Vice President
Kazuyoshi TachibanaManaging Executive OfficerToshifumi MikayamaManaging Executive Officer
More Company Profile & Key Executives for 4151

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil